Investor Presentation

38 Investor presentation First six months of 2022 GLP-1 and SGLT-2i have been driving the value growth of the global diabetes care market Estimated global number of patients Estimated global diabetes value market 192 million CAGR: +4% $ CAGR: +5% 218 million USD 47 billion USD 55 billion 2018 Insulin 2021 GLP-1 SGLT-2i 2018 DPP-4i 2021 Traditional OADs Novo NordiskⓇ Diabetes market dynamics Continued strong growth momentum in GLP-1 and SGLT-2i segments, but from a larger base DPP-4i segment to have first patent expiries on key products within the coming two years Flat insulin volume growth and continued insulin pricing pressure Note: GLP-1+basal insulin combination sales are included in insulin; Traditional OADS include metformin, SU and TZDS. CAGR: Compound annual growth rates. OAD: Oral anti-diabetes Sources: Patient data is Novo Nordisk estimates; Value data: 2018 and 2021 data based on company reported sales for insulin, GLP-1, SGLT-2i and DPP-4i and IQVIA data for traditional OADS as of December 2018 and 2021

View entire presentation